Cancer Biology, Metabolism, and Therapeutics

Cancer pathogenesis is the biological process by which normal cells transform into malignant cancer cells. This is a multi-step process driven by the accumulation of genetic and epigenetic alterations. The core drivers are:

• Gain-of-function mutations in Oncogenes: Normal genes (proto-oncogenes) that promote cell growth (e.g., RAS, MYC, EGFR) become hyperactive.
• Loss-of-function mutations in Tumor Suppressor Genes: Genes that normally halt cell division or trigger cell death (e.g., TP53, RB1) are inactivated.
• Evasion of Apoptosis: Cells lose the ability to undergo programmed cell death despite having severe DNA damage.
• Limitless Replicative Potential: Cancer cells reactivate telomerase, an enzyme that maintains telomere length, allowing them to divide infinitely without aging.

As these mutations accumulate, cells acquire the "Hallmarks of Cancer," enabling them to sustain proliferative signaling, induce angiogenesis (building new blood vessels), and eventually invade surrounding tissues and metastasize.

A tumor is not just a mass of mutant cancer cells; it is a complex, rogue organ. The Tumor Microenvironment (TME) is the cellular and non-cellular environment surrounding the tumor cells. It consists of:

• Stroma: Cancer-associated fibroblasts (CAFs), which secrete growth factors and remodel the extracellular matrix (ECM) to make it stiffer and more conducive to tumor spread.
• Immune Cells: T-cells, B-cells, Natural Killer (NK) cells, and macrophages. While some try to fight the tumor, the tumor secretes cytokines (like TGF-β and IL-10) to suppress them.
• Vasculature: Tumors secrete VEGF (Vascular Endothelial Growth Factor) to sprout new, albeit leaky and chaotic, blood vessels to supply oxygen and nutrients.
• Extracellular Matrix (ECM): The structural scaffold that is constantly broken down and rebuilt by tumor enzymes (MMPs) to allow cancer cells to escape.

Macrophages are immune cells that engulf and digest cellular debris and pathogens. In the context of cancer, they are called Tumor-Associated Macrophages (TAMs) and exist on a spectrum between two primary phenotypes:

• M1 Macrophages (Classical Activation): These are anti-tumor. They are activated by IFN-γ and bacterial signals. They produce pro-inflammatory cytokines (IL-12, TNF-α), reactive oxygen species (ROS), and nitric oxide to kill cancer cells and present antigens to T-cells.
• M2 Macrophages (Alternative Activation): These are pro-tumor. The tumor microenvironment secretes factors (IL-4, IL-13, lactic acid) that force macrophages into the M2 state. M2 macrophages suppress the immune system (via IL-10, TGF-β), promote tissue repair, and stimulate angiogenesis (new blood vessels), effectively helping the tumor grow and spread.

In most aggressive solid tumors, the balance heavily shifts from M1 to M2.

Normally, cells use glycolysis in the cytoplasm (producing a little ATP) followed by Oxidative Phosphorylation (OXPHOS) in the mitochondria (producing a lot of ATP) if oxygen is present.

Otto Warburg observed that cancer cells preferentially rely on aerobic glycolysis—they metabolize glucose into lactate even when abundant oxygen is available. While this produces much less ATP per glucose molecule (2 ATP vs. 36 ATP), it happens 10-100 times faster.

More importantly, it provides the cancer cell with intermediate building blocks (nucleotides, amino acids, lipids) necessary for rapid cell division. The secreted lactate also acidifies the TME, suppressing immune cells.

The Reverse Warburg Effect is a multi-compartmental metabolic model. In this scenario, the cancer cells themselves don't entirely rely on glycolysis. Instead, they induce oxidative stress in the surrounding stromal cells (like Cancer-Associated Fibroblasts, or CAFs).

This stress forces the fibroblasts to undergo aerobic glycolysis (the Warburg effect), causing them to produce and secrete massive amounts of energy-rich metabolites like lactate, pyruvate, and ketone bodies.

The cancer cells then import these metabolites and use them in their own mitochondria for highly efficient Oxidative Phosphorylation (OXPHOS).

Oral cancer is predominantly Oral Squamous Cell Carcinoma (OSCC), arising from the mucosal lining of the mouth.

• Etiology: Primary risk factors include tobacco use, heavy alcohol consumption (which act synergistically), betel quid chewing (common in South/Southeast Asia), and high-risk Human Papillomavirus (HPV) infections, particularly HPV-16 (mostly in the oropharynx).
• Molecular Drivers: Tobacco and alcohol cause DNA adducts and oxidative damage, frequently mutating the TP53 tumor suppressor gene. HPV-driven oral cancers involve viral proteins E6 (which degrades p53) and E7 (which binds Rb), forcing the cell into the S-phase of the cell cycle.
• Field Cancerization: Because the entire oral cavity is exposed to the same carcinogens (like smoke), multiple patches of pre-malignant cells can exist. This is why oral cancers often recur or present with secondary primary tumors.
• Standard Treatment: Early stage (T1/T2) OSCC is treated with Wide Local Excision. Advanced stages (T3/T4 or positive lymph nodes) require extensive surgical resection (with neck dissection) followed by Concurrent Chemoradiotherapy (CCRT) to eliminate microscopic regional disease.

Oral cancer is formally staged using the AJCC TNM Staging System. This system determines the extent of the disease and guides treatment decisions.

Immunohistochemistry (IHC) uses specific antibodies attached to colorful dyes to detect the presence of specific proteins in tissue samples. For Oral Squamous Cell Carcinoma (OSCC), the following antibodies are crucial for diagnosis and profiling:

The primary curative treatment for Oral Squamous Cell Carcinoma is surgical resection. The pathologist measures the distance from the outermost invasive edge of the tumor to the physical cut edge of the removed tissue. This is called the Surgical Margin.

While squamous cell carcinoma dominates the oral mucosa, the salivary glands (parotid, submandibular, sublingual, and minor glands) give rise to a distinct and diverse group of neoplasms. A general rule: the smaller the gland, the higher the chance a tumor in it is malignant.

While "Carcinomas" arise from epithelial tissue (the surface lining), "Sarcomas" arise from mesenchymal tissues—the deep connective tissues like bone, cartilage, muscle, and blood vessels. They are rare in the oral cavity but highly aggressive.

The oral cavity and maxillofacial region are highly innervated (e.g., branches of the Trigeminal and Facial nerves). Tumors arising from the nerve sheath—specifically Schwann cells and perineurial fibroblasts—frequently present as painless submucosal nodules, often on the tongue, lips, or buccal mucosa.

Cisplatin is a platinum-based antineoplastic drug widely used for solid tumors, including oral cancer. Once inside the cell, the chloride ligands of cisplatin are displaced by water, making the molecule highly reactive. It binds to the N7 reactive center on purine residues (primarily guanine) of DNA.

Consequently, DNA replication and transcription halt. The cell senses this massive, unrepairable DNA damage and activates the p53 pathway, which triggers apoptosis (programmed cell death).

T-cells are the primary immune cells responsible for killing cancer cells. To prevent T-cells from attacking normal healthy tissue (autoimmunity), they have an "off switch" receptor called PD-1 (Programmed Cell Death Protein 1).

Cancer cells cleverly hijack this system by expressing large amounts of PD-L1 (the ligand for PD-1) on their surface. When a T-cell approaches the cancer cell to kill it, the tumor's PD-L1 binds to the T-cell's PD-1. This interaction sends an inhibitory signal to the T-cell, causing "T-cell exhaustion"—the T-cell becomes deactivated and ignores the tumor.

PD-1 Inhibitors (e.g., Pembrolizumab, Nivolumab) are monoclonal antibodies that bind to the PD-1 receptor on T-cells, physically blocking the tumor from pressing the "off switch." This reactivates the T-cells, allowing them to recognize and destroy the tumor.

Concurrent Chemoradiotherapy (CCRT) is the simultaneous administration of chemotherapy (typically Cisplatin) and ionizing radiation. This approach is superior to either treatment alone because of Radiosensitization.

Key Clinical Indications: Positive surgical margins, Extranodal Extension (ENE), or advanced nodal disease (N2-N3).